hotspot -WSS

hotspot

author：explore 2025-09-03 09:24:56 - browse：93

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： UnitedHealth CEO's Medicaid comments send insurer stocks diving

hotspot

WSS

BD to buy Edwards patient monitoring unit for $4.2 billion

Structure Therapeutics oral GLP

STAT Summit: GSK CEO on pharma giant's new direction

Why health workers in Gaza are injured or die at high rates

FTC loses bid to block Novant's North Carolina hospital merger

STAT wants to know your pick for a great summer read or listen

knowledge

hotspot

focus

The cancer drug shortage isn’t new — and neither are the solutions

ASCO Daily Recap: CAR

Peter Hotez and the public health issue of online harassment

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Virginia high school admissions case could be legal follow

The explosion of genetic testing requires a new approach

As demand for Covid shots wanes, Moderna seeks its next success

Illumina board agrees to spin off Grail, as divestment plans proceed

DIEP, the 'gold standard' of breast reconstruction, is under threat

STAT Summit: GSK CEO on pharma giant's new direction

hotspot

NIH confirmation hearing shows politicization of research

FDA gives detailed accounting of AI

Illumina board agrees to spin off Grail, as divestment plans proceed

ASCO Daily Recap: CAR

BD to buy Edwards patient monitoring unit for $4.2 billion

The most pressing bird flu mysteries scientists want answered

hotspot

hotspot

knowledge

knowledge